ReviewCurrent atherosclerosis reports2020
Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis.
Review in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.Molecules (Basel, Switzerland) · 2024Pooled it
- Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial.F1000Research · 2021Trial
- Article
- Joint effect of hepatic steatosis index and triglyceride glucose index on cardio-renal outcomes: a real-world study.Journal of diabetes and metabolic disorders · 2026Article
- Global Co-Occurrence Patterns of Ischemic Heart Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease: Spatial Clusters, Risk Factors, and Quality-of-Care Index.Journal of the American Heart Association · 2026Article
- Machine Learning-Based Biomarker Identification for Early Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease.The Journal of clinical endocrinology and metabolism · 2025Article
- Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease.World journal of cardiology · 2025Review
- Relationships among fibrosis-4, triglyceride-glucose index, and cardiovascular disease: Evidence from the NHANES 2003-2018.American journal of preventive cardiology · 2025Article
- Metabolic dysfunction-associated steatotic liver disease and increased risk of atrial fibrillation in the elderly: A longitudinal cohort study.International journal of cardiology. Heart & vasculature · 2025Article
- Relationship between Liver Fibrosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease and Subclinical Atherosclerosis.Arquivos brasileiros de cardiologia · 2025Article
- Unveiling the Link between MASLD-Associated Liver Fibrosis and Subclinical Atherosclerosis.Arquivos brasileiros de cardiologia · 2025Article
- Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort.Frontiers in endocrinology · 2025Article
- Diagnostic value of CT liver-to-spleen attenuation ratio in patients with non-alcoholic fatty liver disease and atherosclerotic plaque.Pakistan journal of medical sciences · 2024Article
- Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.Journal of clinical medicine · 2024Article
- Assessment of left atrial function by two-dimensional speckle tracking echocardiography in patients with metabolic-associated fatty liver disease.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum.Frontiers in endocrinology · 2024Article
- Editorial: Bile acids in obesity-related diseases.Frontiers in endocrinology · 2024Article
- Natural products in atherosclerosis therapy by targeting PPARs: a review focusing on lipid metabolism and inflammation.Frontiers in cardiovascular medicine · 2024Review
- Systemic immune-inflammation index mediates the association between metabolic dysfunction-associated fatty liver disease and sub-clinical carotid atherosclerosis: a mediation analysis.Frontiers in endocrinology · 2024Article
- Dietary inflammatory index (DII) is correlated with the incidence of non-alcoholic fatty liver disease (NAFLD): Fasa PERSIAN cohort study.BMC nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe summarize best data of the association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). RECENT
findingsNAFLD has been linked with insulin resistance, obesity, and metabolic syndrome, conditions known to be associated with CVD and subclinical atherosclerosis. The rising evidence of the association between NAFLD and subclinical CVD may suggest that NAFLD is not only a marker but also may be actively involved in pathogenesis of CVD. It is an overview of previous studies assessing relationships between NAFLD and markers of cardiovascular disease, as the presence of coronary artery calcification, increased arterial stiffness, and elevated carotid media thickness, in order to better understand the interplay between these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.